KLRG2 siRNA (h): sc-89814



The Power to Question

BACKGROUND

KLRG2 (killer cell lectin-like receptor subfamily G member 2), also known as CLEC15B (C-type lectin domain family 15 member B), is a 409 amino acid single-pass membrane protein that contains one C-type lectin domain. Existing as two alternatively spliced isforms, the gene encoding KLRG2 maps to human chromosome 7, which houses over 1,000 genes and comprises nearly 5% of the human genome. Chromosome 7 has been linked to Osteogenesis imperfecta, Pendred syndrome, Lissencephaly, Citrullinemia and Shwachman-Diamond syndrome. The deletion of a portion of the q arm of chromosome 7 is associated with Williams-Beuren syndrome, a condition characterized by mild mental retardation, an unusual comfort and friendliness with strangers and an elfin appearance. Deletions of portions of the q arm of chromosome 7 are also seen in a number of myeloid disorders including cases of acute myelogenous leukemia and myelodysplasia.

REFERENCES

- 1. Tsipouras, P., et al. 1983. Restriction fragment length polymorphism associated with the pro α 2l gene of human type I procollagen. Application to a family with an autosomal dominant form of osteogenesis imperfecta. J. Clin. Invest. 72: 1262-1267.
- Liang, H., et al. 1998. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. Proc. Natl. Acad. Sci. USA 95: 3781-3785.
- Iwasaki, S., et al. 2001. Long-term audiological feature in Pendred syndrome caused by PDS mutation. Arch. Otolaryngol. Head Neck Surg. 127: 705-708.
- Osborne, L.R., et al. 2006. Williams-Beuren syndrome diagnosis using fluorescence in situ hybridization. Methods Mol. Med. 126: 113-128.
- 5. Reiner, O., et al. 2006. Lissencephaly 1 linking to multiple diseases: mental retardation, neurodegeneration, schizophrenia, male sterility, and more. Neuromolecular Med. 8: 547-565.
- Gilbert-Dussardier, B. 2006. Williams-Beuren syndrome. Rev. Prat. 56: 2102-2106.
- Leone, G., et al. 2007. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92: 1389-1398.

CHROMOSOMAL LOCATION

Genetic locus: KLRG2 (human) mapping to 7q34.

PRODUCT

KLRG2 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see KLRG2 shRNA Plasmid (h): sc-89814-SH and KLRG2 shRNA (h) Lentiviral Particles: sc-89814-V as alternate gene silencing products.

For independent verification of KLRG2 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-89814A, sc-89814B and sc-89814C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

KLRG2 siRNA (h) is recommended for the inhibition of KLRG2 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

KLRG2 (B-12): sc-514346 is recommended as a control antibody for monitoring of KLRG2 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor KLRG2 gene expression knockdown using RT-PCR Primer: KLRG2 (h)-PR: sc-89814-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**